Exchange: NASDAQ·Updated 07:39 PM EDT
News
all
press releases
ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Short Interest Down 39.8% in March
ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB - Get Free Report) was the target of a significant decrease in short interest during the month of March. As of March 13th, there was short interest...
MarketBeat
More News
ProShares Ultra Nasdaq Biotechnology Declares Quarterly Dividend of $0.01 (NASDAQ:BIB)
ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) announced a quarterly dividend on Tuesday, March 24th. Shareholders of record on Wednesday, March 25th will be given a dividend of 0.0071 per share...
MarketBeat
ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Stock Price Cross Below 50 Day Moving Average - What's Next?
ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Stock Cross Below 50 Day Moving Average - Time to Sell...
MarketBeat
ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Stock Pass Below 50 Day Moving Average - Time to Sell?
ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Share Price Cross Below 50-Day Moving Average - Here's Why...
MarketBeat
ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Short Interest Down 27.9% in January
ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB - Get Free Report) was the recipient of a large decrease in short interest in January. As of January 30th, there was short interest totaling 21,087...
MarketBeat
Short Interest in ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Declines By 29.2%
ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB - Get Free Report) saw a large decrease in short interest in the month of December. As of December 15th, there was short interest totaling 28,385...
MarketBeat
ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) to Issue Quarterly Dividend of $0.13
ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) declared a quarterly dividend on Tuesday, December 23rd. Shareholders of record on Wednesday, December 24th will be paid a dividend of 0.1346 per...
MarketBeat
How Abivax Went From Biotech Nobody To M&A Bullseye After A Single Blockbuster Readout This Year
A 1,900% rally, Phase 3 wins, and takeover chatter around Eli Lilly have transformed Abivax from a risky clinical bet into a strategic asset with real optionality.
Stocktwits
ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Shares Cross Above 50 Day Moving Average - Here's Why
ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Stock Pass Above 50 Day Moving Average - What's Next...
MarketBeat
ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Shares Cross Above 50 Day Moving Average - Here's Why
ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Stock Price Pass Above 50 Day Moving Average - Time to Sell...
MarketBeat

Advertisement|Remove ads.